The Association of Biotechnology Companies BioForum launches the #polishbiotech online database as the largest association of biotech companies in Poland.
We are the first point of contact for entrepreneurs in the biotechnology industry and we constantly support the Polish biotechnology community 👩🔬 👨🔬
SIGN UP HERE 👇👇👇
"*" indicates required fields
Ryvu Therapeutics S.A.
+ business areaBioPharma R&D+Services
+ annual revenue
2020 – 36,950,000 PLN
2021 – 35,410,000 PLN
2022 – 68,440,000 PLN
2023 – 67,300,000 PLN
2024 – 101,960,000 PLN
+ workforce (estimated if not reported)
2020 – 161
2021 – 190
2022 – 215
2023 – 270
2024 – 328
+ depreciation & amortization
2020 – 12,357,000 PLN
2021 – 12,561,000 PLN
2022 – 12,900,000 PLN
2023 – 10,971,000 PLN
2024 – 10,496,000 PLN
Polish clinical-stage biopharma developing small-molecule cancer therapies, including RVU120 (CDK8/CDK19 inhibitor) and SEL24 (PIM/FLT3 inhibitor, licensed to Menarini). Founded in 2007, headquartered in Kraków, and listed on the Warsaw Stock Exchange.